Befotertinib
- Generic Name
- Befotertinib
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 592
- Registration Number
- NCT06561620
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 23
- Registration Number
- NCT06517953
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05007938
- Locations
- 🇨🇳
Feng Ye, Xiamen, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath